GlassScriptPhysician profile
Jack J Kleid
NPI 1033381124
$5,315.95
in general payments reported to CMS, 2019-2025
24 companies · $663 in 2025
The $663 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $634 · 2021: $1,236 · 2022: $819 · 2023: $877 · 2024: $846 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,362 · Education: $23.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,362.13 |
| Education | $23.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,372.47 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $746.13 | 2021-2025 | |
| Pfizer INC. | $677.05 | 2019-2025 | |
| Novo Nordisk INC | $393.36 | 2021-2024 | Ozempic, Rybelsus |
| Amarin Pharma, INC. | $342.03 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $292.74 | 2021-2025 | Verquvo, Capvaxive |
| Heartflow, INC. | $225.95 | 2023-2025 | Ffrct |
| Lilly USA, LLC | $198.01 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Cvrx, INC. | $196.65 | 2023-2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $144.67 | 2020-2023 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $138.80 | 2021-2024 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.44 | 2021-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $89.54 | 2019-2024 | Xarelto |
| Azurity Pharmaceuticals, INC. | $78.94 | 2023-2025 | Edarbi, Edarbi |
| Arbor Pharmaceuticals, INC. | $75.07 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $54.16 | 2023-2024 | Hillrom - Cardiac Ambulatory Monitor |
| Alnylam Pharmaceuticals INC. | $29.91 | 2023 | Amvuttra |
| Abbott Laboratories | $26.03 | 2019 | |
| Sanofi-Aventis U.S. LLC | $23.00 | 2019 | |
| Glaxosmithkline, LLC. | $22.23 | 2025 | Shingrix |
| Celgene Corporation | $20.90 | 2023 | Camzyos |
| Nevro Corp. | $19.01 | 2022 | |
| Esperion Therapeutics, INC. | $18.23 | 2021 | |
| Currax Pharmaceuticals LLC | $16.63 | 2025 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Kleid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.